Radhakrishnan Sabarinath Venniyil, Bhardwaj Neelam, Luetkens Tim, Atanackovic Djordje
Multiple Myeloma Program & Cancer Immunotherapy, Hematology and Hematologic Malignancies, University of Utah/Huntsman Cancer Institute, Salt Lake City, UT, USA.
Oncoimmunology. 2017 Mar 28;6(5):e1308618. doi: 10.1080/2162402X.2017.1308618. eCollection 2017.
Treatment for multiple myeloma (MM) has significantly advanced in the last decade with the introduction of proteasome inhibitors and immunomodulatory therapies. Unfortunately, MM continues to cause significant morbidity and most patients eventually succumb to the disease. As in other areas of cancer, immunotherapy in MM has also evolved and holds promise to deliver long-lasting remissions or even cure. The signaling lymphocyte activation molecules (SLAM) family of surface proteins represents a group of potential targets for immunotherapy in MM as some of the family members are expressed consistently on plasma cells and also on myeloma propagating pre-plasma cells. Here, we review the SLAM family members in detail, describe their tissue distribution, biologic pathways, as well as relevant pre-clinical studies and clinical trials in MM. Our review demonstrates the value of SLAM family receptors as potential targets for anti-myeloma immunotherapies and outlines how immunotherapeutic approaches can be developed.
在过去十年中，随着蛋白酶体抑制剂和免疫调节疗法的引入，多发性骨髓瘤（MM）的治疗取得了显著进展。不幸的是，MM仍然会导致严重的发病率，并且大多数患者最终会死于该疾病。与癌症的其他领域一样，MM的免疫疗法也在不断发展，有望实现长期缓解甚至治愈。信号淋巴细胞激活分子（SLAM）家族的表面蛋白是MM免疫疗法的一组潜在靶点，因为该家族的一些成员在浆细胞以及骨髓瘤增殖前体细胞上持续表达。在这里，我们详细回顾了SLAM家族成员，描述了它们的组织分布、生物学途径，以及MM相关的临床前研究和临床试验。我们的综述证明了SLAM家族受体作为抗骨髓瘤免疫疗法潜在靶点的价值，并概述了如何开发免疫治疗方法。
